Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501869 | 0.92 | ALDH1A1 (0.45) | CASP3MAPK14KDM4EGRM5MEN1 | |
| SCHEMBL13678554 | 0.91 | MAPK14 (0.46) | CASP3MAPK14KDM4EKMT2A | |
| SCHEMBL4513533 | 0.90 | MAPK14 (0.43) | CASP3MAPK14KDM4EMEN1GAA | |
| SCHEMBL4505724 | 0.90 | MAPK14 (0.43) | CASP3MAPK14KDM4EMEN1GAA | |
| SCHEMBL4513443 | 0.88 | GAA (0.49) | MAPK14KDM4EMEN1GAAKMT2A | |
| SCHEMBL4499526 | 0.86 | MAPK14 (0.48) | MAPK14KDM4E | |
| SCHEMBL4519474 | 0.85 | MAPK14 (0.51) | MAPK14KDM4EGAA | |
| SCHEMBL4512677 | 0.83 | CASP3 (0.52) | CASP3KDM4EGRM5MEN1APAF1 | |
| SCHEMBL4504766 | 0.83 | MAPK14 (0.40) | MAPK14KDM4EGRM5MEN1GAA | |
| SCHEMBL4516348 | 0.82 | CD274 (0.43) | CASP3KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | CASP3 1096/4885MAPK14 117/4885KDM4E 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.